Botox® Faces Fresh Competition
Long considered the industry icon for relaxing facial features to eliminate wrinkles, Botox now has some stiff competition.
A new botulinum toxin has been approved for both cosmetic and therapeutic use in the United States.
Dysport, which is an injectable toxin that helps reduce frown lines from muscle contraction, will be a competitor of Botox cosmetic.
Arizona-based Medicis has licensed Dysport from Ipsen, the French company that developed the drug.
Although Dysport and Botox cosmetic are similar, the onset of action may be quicker in the newly approved product.
Dysport is expected to be available to consumers by mid-summer, and the packaging will include the new in-box labeling that specifies the toxin can spread from the injection site, as mentioned in our earlier story.
Nearly two and a half million Americans had cosmetic-related Botox injections in 2008, and Dysport hopes to begin claiming a share of that market in just 60 days, when it becomes available in the U.S.